Payment overview · 2025
General Payments
$2,365.50
105 reported records · 24 companies
Healthcare provider profile · identity verified
Vigen Khojayan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GLENDALE, CA · NPI 1477723203
Verified facts
What the public records show
CMS Open Payments records show Vigen Khojayan, M.D. received $2,365.50 in general payments during 2025 across 105 reported records.
AstraZeneca Pharmaceuticals LP accounted for 11.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Jardiance, Kerendia, Linzess, Nexletol, Otezla, Ozempic, Trelegy Ellipta, Ubrelvy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 288 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 283 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 283 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Ozempic by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $262.55 | 11.1% | 12 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $256.23 | 10.8% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $219.78 | 9.3% | 11 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $183.96 | 7.8% | 17 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $178.86 | 7.6% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $153.59 | 6.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $152.49 | 6.5% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.32 | 5.1% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $111.64 | 4.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $103.41 | 4.4% | 5 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $81.14 | 3.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.03 | 3.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $78.81 | 3.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.46 | 2.4% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.44 | 2.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $53.24 | 2.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.86 | 1.8% | 2 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $35.30 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.04 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.75 | 1.1% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $24.43 | 1.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.44 | 0.9% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.87 | 0.9% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $17.86 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,323.00 | 104 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $256.23 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $199.54 | 9 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $183.96 | 17 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $178.86 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $153.59 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $152.49 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $133.55 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.98 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $113.99 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $111.64 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $107.07 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $101.80 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $93.65 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.98 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.21 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $83.98 | 5 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $81.14 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $78.81 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $53.44 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53.24 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.88 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.86 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.59 | 2 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $35.30 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.11 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $17.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 79 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 104 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 283 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 288 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 199 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
288 | 47 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
47 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
112 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
283 | 41 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
283 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
199 | 26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
104 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1749 | 253 |
| Amlodipine Besylate | Amlodipine Besylate | 1260 | 186 |
| Losartan Potassium | Losartan Potassium | 945 | 152 |
| Hydralazine Hcl | Hydralazine Hcl | 889 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 854 | 101 |
| Metformin Hcl | Metformin Hcl | 745 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 582 | 84 |
| Omeprazole | Omeprazole | 570 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 556 | 83 |
| Gabapentin | Gabapentin | 527 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 527 | 75 |
| Diclofenac Sodium | Diclofenac Sodium | 513 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 488 | 82 |
| Ibuprofen | Ibuprofen | 472 | 82 |
| Vascepa | Icosapent Ethyl | 471 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 453 | 80 |
| Icosapent Ethyl | Icosapent Ethyl | 452 | 94 |
| Allopurinol | Allopurinol | 441 | 59 |
| Ezetimibe | Ezetimibe | 415 | 58 |
| Lisinopril | Lisinopril | 407 | 64 |
| Sertraline Hcl | Sertraline Hcl | 362 | 43 |
| Furosemide | Furosemide | 358 | 61 |
| Meclizine Hcl | Meclizine Hcl | 320 | 53 |
| Celecoxib | Celecoxib | 318 | 48 |
| Carvedilol | Carvedilol | 294 | 52 |
| Simvastatin | Simvastatin | 289 | 38 |
| Linzess | Linaclotide | 288 | 47 |
| Jardiance | Empagliflozin | 283 | 41 |
| Alendronate Sodium | Alendronate Sodium | 266 | 30 |
| Famotidine | Famotidine | 263 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 262 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 252 | 40 |
| Pitavastatin Calcium | Pitavastatin Calcium | 246 | 40 |
| Tradjenta | Linagliptin | 240 | 34 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 230 | 46 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 229 | 37 |
| Dexlansoprazole Dr | Dexlansoprazole | 228 | 36 |
| Alprazolam | Alprazolam | 202 | 32 |
| Lorazepam | Lorazepam | 202 | 32 |
| Januvia | Sitagliptin Phosphate | 200 | 26 |
| Ozempic | Semaglutide | 199 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 198 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 198 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 193 | 34 |
| Diclofenac Potassium | Diclofenac Potassium | 184 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 183 | 27 |
| Atenolol | Atenolol | 179 | 23 |
| Azithromycin | Azithromycin | 171 | 122 |
| Montelukast Sodium | Montelukast Sodium | 171 | 23 |
| Tramadol Hcl | Tramadol Hcl | 170 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 170 | 37 |
| Clonidine Hcl | Clonidine Hcl | 168 | 21 |
| Potassium Chloride | Potassium Chloride | 165 | 31 |
| Finasteride | Finasteride | 156 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 29 |
| Donepezil Hcl | Donepezil Hcl | 149 | 24 |
| Meloxicam | Meloxicam | 137 | 26 |
| Benazepril Hcl | Benazepril Hcl | 129 | 17 |
| Eliquis | Apixaban | 127 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 127 | 18 |
| Mirtazapine | Mirtazapine | 126 | 16 |
| Glipizide | Glipizide | 122 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 36 |
| Propranolol Hcl | Propranolol Hcl | 118 | 13 |
| Glimepiride | Glimepiride | 117 | 16 |
| Clonazepam | Clonazepam | 113 | 15 |
| Farxiga | Dapagliflozin Propanediol | 112 | 17 |
| Metformin Er Gastric | Metformin Hcl | 106 | 20 |
| Gemtesa | Vibegron | 104 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 19 |
| Repatha Sureclick | Evolocumab | 102 | 19 |
| Methimazole | Methimazole | 97 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 96 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 14 |
| Enalapril Maleate | Enalapril Maleate | 89 | 11 |
| Fenofibrate | Fenofibrate | 89 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 14 |
| Ketoconazole | Ketoconazole | 88 | 18 |
| Memantine Hcl Er | Memantine Hcl | 86 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 85 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 83 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | suppressed |
| Naproxen | Naproxen | 80 | 13 |
| Creon | Lipase/Protease/Amylase | 79 | 20 |
| Fenofibrate | Fenofibrate,micronized | 79 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 21 |
| Hydrocortisone | Hydrocortisone | 78 | 18 |
| Memantine Hcl | Memantine Hcl | 78 | 12 |
| Livalo | Pitavastatin Calcium | 77 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 15 |
| Trazodone Hcl | Trazodone Hcl | 76 | 12 |
| Nifedipine Er | Nifedipine | 74 | 14 |
| Chlorthalidone | Chlorthalidone | 72 | 15 |
| Gemfibrozil | Gemfibrozil | 72 | suppressed |
| Synthroid | Levothyroxine Sodium | 71 | 12 |
| Brilinta | Ticagrelor | 70 | suppressed |
| Pregabalin | Pregabalin | 70 | 15 |
| Spironolactone | Spironolactone | 70 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 11 |
| Temazepam | Temazepam | 66 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 65 | 13 |
| Amoxicillin | Amoxicillin | 65 | 52 |
| Aripiprazole | Aripiprazole | 64 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 63 | suppressed |
| Colchicine | Colchicine | 62 | suppressed |
| Ranolazine Er | Ranolazine | 62 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 62 | 17 |
| Valsartan | Valsartan | 61 | 11 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 60 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 59 | suppressed |
| Myrbetriq | Mirabegron | 59 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 58 | suppressed |
| Dutasteride | Dutasteride | 57 | suppressed |
| Dayvigo | Lemborexant | 56 | suppressed |
| Loperamide | Loperamide Hcl | 53 | 15 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 52 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 11 |
| Lansoprazole | Lansoprazole | 50 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 49 | 14 |
| Divalproex Sodium | Divalproex Sodium | 47 | suppressed |
| Nitroglycerin | Nitroglycerin | 47 | suppressed |
| Procto-Med Hc | Hydrocortisone | 47 | 11 |
| Prolia | Denosumab | 47 | 32 |
| Baclofen | Baclofen | 45 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Ramipril | Ramipril | 45 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 45 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 45 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Febuxostat | Febuxostat | 42 | suppressed |
| Clotrimazole | Clotrimazole | 41 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 41 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Nexletol | Bempedoic Acid | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 13 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 36 | 12 |
| Risperidone | Risperidone | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 13 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Edarbi | Azilsartan Medoxomil | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Indapamide | Indapamide | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 11 |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Nexium | Esomeprazole Magnesium | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 23 | suppressed |
| Ibu | Ibuprofen | 23 | suppressed |
| Dexilant | Dexlansoprazole | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Multaq | Dronedarone Hcl | 21 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 20 | suppressed |
| Crestor | Rosuvastatin Calcium | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Alogliptin | Alogliptin Benzoate | 18 | suppressed |
| Cyclosporine | Cyclosporine | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Mitigare | Colchicine | 14 | suppressed |
| Mupirocin | Mupirocin Calcium | 14 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Calcipotriene | Calcipotriene | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zileuton Er | Zileuton | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 11 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,365.50 · 105 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AFREZZA, AIRSUPRA, BREZTRI, CREON, Dexcom G6 Transmitter, Fibroscan, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LINZESS, LOREEV XR, NEXLETOL, OTEZLA, Ozempic, QULIPTA, Quviviq, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZENPEP, ZEPBOUND, ZORYVE, ZTLido | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error